论文部分内容阅读
目的 :探讨CYFRA2 1 1在肺癌、喉癌和消化道肿瘤中的诊断价值。方法 :应用酶联免疫方法对82例肺癌、18例喉癌和 74例消化道肿瘤测试血清CYFRA2 1 1水平。结果 :①肺癌CYFRA2 1 1阳性率为 79.3% ,特异性为 92 .5% ,准确率为 83.6 % ,明显高于其他肿瘤 ;②肿瘤转移患者血清CYFRA2 1 1水平明显高于未转移患者 ;③肺癌治疗前后血清CYFRA2 1 1水平有显著差异 ,治疗后明显下降 ;④非小细胞肺癌血清CYFRA2 1 1水平明显高于小细胞肺癌。结论 :CYFRA2 1 1是诊断肺癌 ,特别是非小细胞肺癌 ,以及观察疗效的一项极有价值的指标。
Objective: To investigate the diagnostic value of CYFRA2 1 1 in lung cancer, laryngeal cancer and gastrointestinal cancer. Methods: The serum levels of CYFRA2 1 1 in 82 lung cancer patients, 18 laryngeal cancer patients and 74 patients with gastrointestinal cancer were tested by enzyme-linked immunosorbent assay. Results: ① The positive rate of CYFRA2 1 1 in lung cancer was 79.3%, the specificity was 92.5%, the accuracy rate was 83.6%, which was significantly higher than that of other tumors. ② The serum levels of CYFRA2 1 1 in patients with tumor metastasis were significantly higher than those without metastasis The levels of serum CYFRA2 1 1 in lung cancer patients before and after treatment were significantly different and decreased significantly after treatment. ④ The serum levels of CYFRA2 1 1 in non-small cell lung cancer were significantly higher than those in small cell lung cancer. Conclusion: CYFRA2 1 1 is a valuable diagnostic marker for lung cancer, especially non-small cell lung cancer.